Literature DB >> 26936845

The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Sule Ozturk Sari1, Orhun Cig Taskin2, Gokcen Gundogdu2, Gulcin Yegen2, Semen Onder2, Metin Keskin3, Sezer Saglam4, Yasemin Ozluk2, Mine Gulluoglu2, Ozgur Mete5,6.   

Abstract

This study investigated the impact of phosphohistone-H3 (PHH3)-assisted mitotic count by comparing its performance with conventional mitotic count and Ki67 score as well as the status of distant metastasis. A total of 43 surgically resected pancreatic neuroendocrine tumors (panNET) with complete follow-up information has been subjected to a standardized assessment with respect to mitotic count (both conventional and PHH3-assisted) and Ki67 score. Five participants assessed mitotic count and the time spent was recorded in both methods. All tumors were assigned to a G1 category of mitotic rate on conventional mitotic count that failed to identify three tumors with a G2 category of mitotic rate on PHH3. Near-perfect and fair agreements were achieved among observers when using PHH3 and conventional method, respectively. The mean time spent to determine mitotic count on PHH3-stained slides was significantly shorter (p < 0.001). The performance of PHH3-assisted mitotic grade category was significant as the three cases with a G2 mitotic category were associated with distant metastasis (p = 0.01). Despite its performance, the PHH3-assisted mitotic count downgraded 17 cases that were classified as G2 based on Ki67 scores in this series. The Ki67 grade category was either the same or higher than the mitotic grade category. Ten patients developed distant metastasis. Eleven tumors exhibited vascular invasion characterized by intravascular tumor cells admixed with thrombus. Our results indicate that PHH3-assisted mitotic count facilitates an accurate mitotic count with a perfect agreement among observers. The small size of this cohort is an important limitation of the current study, a G2 mitotic grade category based on PHH3 immunohistochemistry was one of the correlates of panNETs with distant metastasis. While the prognostic impact of PHH3-assisted mitotic count needs to be clarified in larger cohorts, Ki67 scores designated higher grade category in all cases; thus, it was the best determinant of the tumor grade. More importantly, the presence of vascular invasion along with the Ki67 grade category was found to be independent predictors of distant metastasis.

Entities:  

Keywords:  Grade; Ki67; Mitotic count; Pancreatic neuroendocrine tumor; Phosphohistone-H3; Vascular invasion

Mesh:

Substances:

Year:  2016        PMID: 26936845     DOI: 10.1007/s12022-016-9424-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  26 in total

1.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

2.  Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis.

Authors:  G Juan; F Traganos; W M James; J M Ray; M Roberge; D M Sauve; H Anderson; Z Darzynkiewicz
Journal:  Cytometry       Date:  1998-06-01

3.  A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram.

Authors:  Trevor A Ellison; Christopher L Wolfgang; Chanjuan Shi; John L Cameron; Peter Murakami; Liew Jun Mun; Aatur D Singhi; Toby C Cornish; Kelly Olino; Zina Meriden; Michael Choti; Luis A Diaz; Timothy M Pawlik; Richard D Schulick; Ralph H Hruban; Barish H Edil
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

4.  Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.

Authors:  Laura H Tang; Mithat Gonen; Cyrus Hedvat; Irvin M Modlin; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

5.  Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation.

Authors:  Ozgur Mete; Sylvia L Asa
Journal:  Mod Pathol       Date:  2011-07-29       Impact factor: 7.842

6.  Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma.

Authors:  Eleonora Duregon; Luca Molinaro; Marco Volante; Laura Ventura; Luisella Righi; Stefania Bolla; Massimo Terzolo; Anna Sapino; Mauro G Papotti
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842

7.  Biomarkers of parathyroid carcinoma.

Authors:  Boban M Erovic; Luke Harris; Mina Jamali; David P Goldstein; Jonathan C Irish; Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2012-12       Impact factor: 3.943

Review 8.  Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging.

Authors:  David S Klimstra
Journal:  Semin Oncol       Date:  2013-02       Impact factor: 4.929

9.  Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.

Authors:  Patricia S Nielsen; Rikke Riber-Hansen; Trine O Jensen; Henrik Schmidt; Torben Steiniche
Journal:  Mod Pathol       Date:  2012-11-23       Impact factor: 7.842

10.  Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors.

Authors:  Paula B Araujo; Sonia Cheng; Ozgur Mete; Stefano Serra; Emilie Morin; Sylvia L Asa; Shereen Ezzat
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

View more
  6 in total

Review 1.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

2.  Clinical and histopathological predictors of outcome in malignant meningioma.

Authors:  Andrea D Maier; Jiri Bartek; Frank Eriksson; Heidi Ugleholdt; Marianne Juhler; Helle Broholm; Tiit I Mathiesen
Journal:  Neurosurg Rev       Date:  2019-03-13       Impact factor: 3.042

3.  Quantitative Assessment of Epithelial Proliferation in Rat Mammary Gland Using Artificial Intelligence Independent of Choice of Proliferation Marker.

Authors:  Tobias H Dovmark; Peter H Kvist; Anne-Marie Mølck; Henning Hvid
Journal:  J Histochem Cytochem       Date:  2022-01-20       Impact factor: 2.479

4.  Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.

Authors:  Anil Aysal; Cihan Agalar; Tufan Egeli; Tarkan Unek; Ilhan Oztop; Funda Obuz; Ozgul Sagol
Journal:  Endocr Pathol       Date:  2021-07-20       Impact factor: 3.943

5.  Tumor Digital Masking Allows Precise Patient Triaging: A Study Based on Ki-67 Scoring in Gastrointestinal Stromal Tumors.

Authors:  Piotr Lewitowicz; Jaroslaw Matykiewicz; Magdalena Chrapek; Dorota Koziel; Agata Horecka-Lewitowicz; Martyna Gluszek-Osuch; Iwona Wawrzycka; Stanisław Gluszek
Journal:  Scanning       Date:  2018-09-02       Impact factor: 1.932

6.  Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index.

Authors:  Dordi Lea; Einar G Gudlaugsson; Ivar Skaland; Melinda Lillesand; Kjetil Søreide; Jon A Søreide
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.